Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Congress Asset Management Co.

Congress Asset Management Co. boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 12.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,348,867 shares of the medical equipment provider’s stock after purchasing an additional 145,297 shares during the quarter. Congress Asset Management Co. owned about 0.58% of Hologic worth $109,879,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norden Group LLC lifted its stake in Hologic by 2,217.0% in the 1st quarter. Norden Group LLC now owns 88,160 shares of the medical equipment provider’s stock worth $6,873,000 after purchasing an additional 84,355 shares in the last quarter. First Trust Direct Indexing L.P. lifted its position in Hologic by 3.3% during the first quarter. First Trust Direct Indexing L.P. now owns 7,882 shares of the medical equipment provider’s stock worth $614,000 after buying an additional 253 shares in the last quarter. Legacy Wealth Asset Management LLC boosted its stake in Hologic by 16.8% during the first quarter. Legacy Wealth Asset Management LLC now owns 3,650 shares of the medical equipment provider’s stock worth $285,000 after buying an additional 526 shares during the last quarter. Leeward Investments LLC MA grew its holdings in Hologic by 112.1% in the 1st quarter. Leeward Investments LLC MA now owns 166,521 shares of the medical equipment provider’s stock valued at $12,982,000 after buying an additional 87,999 shares in the last quarter. Finally, HB Wealth Management LLC increased its stake in shares of Hologic by 8.6% in the 1st quarter. HB Wealth Management LLC now owns 5,463 shares of the medical equipment provider’s stock worth $426,000 after acquiring an additional 431 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI increased their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.50.

Insider Transactions at Hologic

In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.75% of the company’s stock.

Hologic Trading Down 0.1 %

NASDAQ HOLX traded down $0.10 during trading on Thursday, hitting $81.05. The stock had a trading volume of 162,750 shares, compared to its average volume of 1,565,688. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $18.92 billion, a PE ratio of 41.52, a PEG ratio of 2.96 and a beta of 0.98. The firm has a 50 day moving average price of $80.93 and a 200 day moving average price of $77.93. Hologic, Inc. has a twelve month low of $65.55 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the business posted $0.93 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.